{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/balanitis/prescribing-information/flucloxacillin/","result":{"pageContext":{"chapter":{"id":"29db55e2-6292-57cc-bb96-e0331bea331b","slug":"flucloxacillin","fullItemName":"Flucloxacillin","depth":2,"htmlHeader":"<!-- begin field a19a0646-4c2d-4909-a0d8-7aed7f764e4e --><h2>Flucloxacillin</h2><!-- end field a19a0646-4c2d-4909-a0d8-7aed7f764e4e -->","summary":"","htmlStringContent":"<!-- begin item 2d8f7dc4-7347-4799-ad2e-733ad4db0e71 --><!-- end item 2d8f7dc4-7347-4799-ad2e-733ad4db0e71 -->","topic":{"id":"4da8d9db-f350-588f-83e8-f5efc3335305","topicId":"eb6c6cd9-3331-4790-a1f9-a11ed643b2b0","topicName":"Balanitis","slug":"balanitis","lastRevised":"Last revised in October 2018","chapters":[{"id":"cf843687-5035-5956-aa14-3d8bacbd404f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"41d01ca1-763c-529e-8026-28dd85d36b16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b9dae5ef-34a6-57ed-bf21-9b9543370ecd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2fc17559-2630-5868-aeda-16c7394d8223","slug":"changes","fullItemName":"Changes"},{"id":"699e0434-3685-5acc-9956-84bc269b6ae0","slug":"update","fullItemName":"Update"}]},{"id":"e0b4a9d5-30c1-589c-b52c-49a537ed88cf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"045bf9d9-1913-57d7-85ac-7dd14d9a6ad1","slug":"goals","fullItemName":"Goals"},{"id":"9242a4e0-3dd3-598a-8015-c1fd35c8ae24","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8d94eba3-36ae-5c38-b3bd-c6fe5a1d1122","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c3fec0e-6d36-590b-a67a-9fde96b588b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd19254a-f9ef-5cd1-af7b-f5226c2474da","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5cc7acd3-6e1c-5b23-9f58-aa1a50f67faa","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10c99e35-8476-5d3d-a309-c80fc5ed5fa7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e615c22a-91ed-5f2c-8d1b-657c4409d5ff","slug":"definition","fullItemName":"Definition"},{"id":"93cf765a-7e94-5ba7-bc6c-d001406aa393","slug":"causes","fullItemName":"Causes"},{"id":"8f5ac951-0e46-5c89-9a50-27eb3f65076f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"feeb11e3-9d66-5d96-a507-c526af44a7f0","slug":"complications","fullItemName":"Complications"}]},{"id":"fb758dfb-b24b-5875-9570-5d6b29ad0606","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7f4b11b8-626e-56eb-9a8d-5aafbb365797","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e0d6dde7-d713-5601-94f9-9a443f7c7cb3","slug":"assessment","fullItemName":"Assessment"},{"id":"a1bd5ccf-b828-59e7-893c-ab9d9e755750","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"de355ac0-0522-5d92-a913-4694aa861fd7","fullItemName":"Management","slug":"management","subChapters":[{"id":"bd1e001e-c6a9-5d54-88ca-ce4a56b46edd","slug":"balanitis-children","fullItemName":"Scenario: Balanitis - children"},{"id":"44e5d982-e2af-5996-ab20-fcc33b89adf1","slug":"balanitis-adults","fullItemName":"Scenario: Balanitis - adults"}]},{"id":"3fdc0cf3-e98c-5a04-9525-c21e93db6dad","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7db80726-7da5-5db6-85b2-e6a211cd3278","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"ad41f201-03ec-5da9-ac6a-1902fa6cad6c","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"29db55e2-6292-57cc-bb96-e0331bea331b","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"41cf5c1f-073b-55f6-bca1-f483e1e31783","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"e2c0e955-b610-5ee0-83a7-020247e8d2e3","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"8384c8ca-522a-546a-971b-71a12dc40ba9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1946dc01-8848-5119-a228-39e16c9c2fee","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a80a505e-c0ca-5472-966a-cfb4d225c502","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f260f355-769f-5d83-8c42-f5b606d7cab7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bedff117-4d2b-5b3b-ae77-431100374dfe","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ccf2a0ba-1a8a-5d6c-829c-a90817d3a0cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c09916ae-40e4-5285-8ce4-a0995eb5225b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fcdbbdd1-c423-5b0c-b610-1ba72cc625c9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3fdc0cf3-e98c-5a04-9525-c21e93db6dad","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a8198f1f-8320-5ec3-9886-9db14619b8aa","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field eef47e9c-ac09-443d-b988-f6f431ce56d6 --><h3>Contraindications and cautions</h3><!-- end field eef47e9c-ac09-443d-b988-f6f431ce56d6 -->","summary":"","htmlStringContent":"<!-- begin item 8a73cc61-f6c0-4195-989b-d1087144e788 --><!-- begin field 2ba6111c-ef96-47b3-9309-7d001b0880e0 --><p><strong>Do not prescribe flucloxacillin to people with:</strong></p><ul><li>A <em>true </em>penicillin hypersensitivity — gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin.</li><li>A history of penicillin-associated jaundice or hepatic dysfunction — flucloxacillin has rarely been associated with hepatitis and cholestatic jaundice. The onset of hepatic reactions may be delayed for several weeks (up to 2 months) after treatment with flucloxacillin has stopped. These reactions are not related to the dose or route of administration of flucloxacillin. Risk factors include treatment for more than two weeks and increasing age.</li></ul><p><strong>Prescribe flucloxacillin with caution to people with:</strong></p><ul><li>Hepatic dysfunction (not flucloxacillin-related) — especially if they are 50 years or over, or have a serious underlying disease.</li><li>Renal impairment — consider dose reduction or a reduction in dosing interval of flucloxacillin in severe renal failure (creatinine clearance less than 10mL/min) due to the risk of neurotoxicity.</li><li>Hypersensitivity to cephalosporins — there is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins, and people have been known to have severe reactions (including anaphylaxis) to both drugs.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">BNF 74, 2017</a>]</p><!-- end field 2ba6111c-ef96-47b3-9309-7d001b0880e0 --><!-- end item 8a73cc61-f6c0-4195-989b-d1087144e788 -->","subChapters":[]},{"id":"851a96b4-d761-53a1-9643-70624274cf06","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c5311408-076b-4c72-97c1-27a0a53f358b --><h3>Adverse effects</h3><!-- end field c5311408-076b-4c72-97c1-27a0a53f358b -->","summary":"","htmlStringContent":"<!-- begin item 2d6d49c4-6442-4ca7-bd0f-ba45fe1fb3eb --><!-- begin field cb20a199-a895-4a4e-bd41-d16c8e011de0 --><ul><li><strong>Common adverse effects of flucloxacillin include:</strong><ul><li>Gastrointestinal disturbances, such as diarrhoea, nausea, vomiting.</li><li>Skin rash.</li><li>Joint pains.</li><li>Serum sickness-like reaction.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Antibiotic-associated colitis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a> for more information.</li><li>Cholestatic jaundice and hepatitis.</li><li>Cerebral irritation, central nervous system toxicity, encephalopathy.</li><li>Coagulation disorders.</li><li>Haemolytic anaemia, leukopenia, thrombocytopenia.</li><li>Interstitial nephritis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">BNF 74, 2017</a>] </p><!-- end field cb20a199-a895-4a4e-bd41-d16c8e011de0 --><!-- end item 2d6d49c4-6442-4ca7-bd0f-ba45fe1fb3eb -->","subChapters":[]},{"id":"e7d58d51-67de-5ca2-b8df-618e89e9084f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ce003325-a794-43d3-ac01-795f918d22a2 --><h3>Drug interactions</h3><!-- end field ce003325-a794-43d3-ac01-795f918d22a2 -->","summary":"","htmlStringContent":"<!-- begin item c2a16a06-ea20-43ad-91ea-1c9893f8a302 --><!-- begin field 339b94dd-c726-4e71-8aa6-0ce913a9f282 --><p><strong>Possible drug interactions with flucloxacillin include:</strong></p><ul><li>Anticoagulants (such as warfarin) — monitor the person’s international normalised ratio (INR) during concurrent use and adjust the warfarin dose accordingly. Prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.</li><li>Methotrexate — there have been rare reports of reduced excretion of methotrexate and acute methotrexate toxicity with concurrent use. One recommended approach is to carry out twice-weekly platelet and white cell count for two weeks initially and measure methotrexate levels if toxicity is suspected.</li><li>Probenecid — probenecid reduces the excretion of penicillin antibiotics, and may raise their serum levels. This may be a beneficial adverse effect but consider any possible detrimental effects of raised levels of penicillin antibiotics.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">BNF 74, 2017</a>] </p><!-- end field 339b94dd-c726-4e71-8aa6-0ce913a9f282 --><!-- end item c2a16a06-ea20-43ad-91ea-1c9893f8a302 -->","subChapters":[]},{"id":"5a80e134-ad44-5a59-8606-f3f665da0830","slug":"dosage-regimens","fullItemName":"Dosage regimens","depth":3,"htmlHeader":"<!-- begin field 82c30d0a-543c-4479-9638-a87701636e43 --><h3>Dosage regimens</h3><!-- end field 82c30d0a-543c-4479-9638-a87701636e43 -->","summary":"","htmlStringContent":"<!-- begin item 63239734-8cea-4821-8c08-a87701636aee --><!-- begin field aec2b0c9-1daf-41c8-aece-a87701636e43 --><ul><li>Oral flucloxacillin is available as 250 mg and 500 mg capsules, and 125 mg per 5 mL and 250 mg per 5 mL oral solution. It should be taken one hour before food or on an empty stomach.</li><li>The dosage regimens for oral flucloxacillin are:<ul><li>Adults and children older than 10 years of age — 250 mg to 500 mg, four times a day for 7 days.</li><li>Children 2–9 years of age — 125 mg to 250 mg, four times a day for 7 days.</li><li>Children 1 month to 1 year of age — 62.5 mg to 125 mg, four times a day for 7 days.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/balanitis/references/\">BNF 74, 2017</a>]</p><!-- end field aec2b0c9-1daf-41c8-aece-a87701636e43 --><!-- end item 63239734-8cea-4821-8c08-a87701636aee -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}